Published in Thromb Res on July 15, 1992
The influence of biomaterials on endothelial cell thrombogenicity. Biomaterials (2007) 1.24
Functional neurokinin 1 receptors for substance P are expressed by human vascular endothelium. J Exp Med (1993) 0.94
Pro-atherogenic shear stress and HIV proteins synergistically upregulate cathepsin K in endothelial cells. Ann Biomed Eng (2014) 0.78
Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest (1978) 5.80
Propagation of the yeast prion-like [psi+] determinant is mediated by oligomerization of the SUP35-encoded polypeptide chain release factor. EMBO J (1996) 5.50
Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest (1977) 5.16
Guidelines for the management of hemophilia. Haemophilia (2012) 5.16
Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem (1992) 4.22
Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest (1977) 4.08
The SUP35 omnipotent suppressor gene is involved in the maintenance of the non-Mendelian determinant [psi+] in the yeast Saccharomyces cerevisiae. Genetics (1994) 4.04
Deletion analysis of the SUP35 gene of the yeast Saccharomyces cerevisiae reveals two non-overlapping functional regions in the encoded protein. Mol Microbiol (1993) 3.76
Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest (1992) 3.50
Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med (1977) 3.43
Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int (2001) 3.07
In vitro propagation of the prion-like state of yeast Sup35 protein. Science (1997) 3.05
Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U S A (1993) 2.77
Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis (1995) 2.65
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
Bacterial adherence to fibronectin and endothelial cells: a possible mechanism for bacterial tissue tropism. J Lab Clin Med (1984) 2.52
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood (1993) 2.48
Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet (1980) 2.47
Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. N Engl J Med (1980) 2.41
Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest (1980) 2.34
Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion (1996) 2.22
Nucleotide sequence of the SUP2 (SUP35) gene of Saccharomyces cerevisiae. Gene (1988) 2.12
Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2010) 2.12
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 2.10
Extracellular matrix proteins (fibronectin, laminin, and type IV collagen) bind and aggregate bacteria. Am J Pathol (1985) 2.08
Isolation and characterization of actin-like protein from yeast Saccharomyces cerevisiae. FEBS Lett (1979) 2.06
Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest (1979) 2.01
Transplantation of discordant xenografts: a review of progress. Immunol Today (1990) 2.00
Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. Ann Intern Med (1983) 1.99
Elevated erythrocyte calcium in sickle cell disease. Nature (1973) 1.97
Chaperones that cure yeast artificial [PSI+] and their prion-specific effects. Curr Biol (2000) 1.96
In vitro granulocyte adherence and in vivo margination: two associated complement-dependent functions. Studies based on the acute neutropenia of filtration leukophoresis. J Exp Med (1977) 1.94
Plasma exchange in the treatment of immune disease. Transfusion (1976) 1.81
Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med (1974) 1.80
Granulocyte aggregometry: a sensitive technique for the detection of C5a and complement activation. Blood (1980) 1.77
Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab Invest (1991) 1.77
Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med (1988) 1.75
Divergence and conservation of SUP2 (SUP35) gene of yeast Pichia pinus and Saccharomyces cerevisiae. Yeast (1991) 1.72
Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest (1991) 1.68
Red pigment of adenine-deficient yeast Saccharomyces cerevisiae. Biochem Biophys Res Commun (1967) 1.67
Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation (1999) 1.66
Reperfusion injury pathophysiology in sickle transgenic mice. Blood (2000) 1.65
Effects of sulfhydryl inhibition on red blood cells. 3. Glutathione in the regulation of the hexose monophosphate pathway. J Biol Chem (1966) 1.62
Sudden blindness in acute pancreatitis. Possible role of complement-induced retinal leukoembolization. Arch Intern Med (1981) 1.62
Interaction between yeast Sup45p (eRF1) and Sup35p (eRF3) polypeptide chain release factors: implications for prion-dependent regulation. Mol Cell Biol (1997) 1.61
Acute hemolytic anemia with rigid red cells in hypophosphatemia. N Engl J Med (1971) 1.60
Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest (1998) 1.58
Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest (1979) 1.54
Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2013) 1.53
Complement activation and pulmonary leukotasis during nylon fiber filtration leukapheresis. Blood (1978) 1.52
Ribosome-bound EF-1 alpha-like protein of yeast Saccharomyces cerevisiae. Eur J Biochem (1991) 1.49
Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb (1991) 1.49
Chlorinated urban water: a cause of dialysis-induced hemolytic anemia. Science (1973) 1.49
Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med (1990) 1.48
Hemodialysis reduces inhibitory effect of plasma ultrafiltrate on LDL oxidation and subsequent endothelial reactions. Kidney Int (2006) 1.46
Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest (1993) 1.45
Abnormal haem binding and globin SH group blockade in unstable haemoglobins. Nature (1968) 1.44
Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J Thromb Haemost (2006) 1.43
Deleterious effects of endotoxin on cultured endothelial cells: an in vitro model of vascular injury. Inflammation (1981) 1.40
Modulation of human aorta smooth muscle cell phenotype: a study of muscle-specific variants of vinculin, caldesmon, and actin expression. Proc Natl Acad Sci U S A (1988) 1.38
Complement-mediated granulocyte dysfunction in paroxysmal nocturnal hemoglobinuria. Blood (1976) 1.37
A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol (1985) 1.35
Acquired resistance to acute oxidative stress. Possible role of heme oxygenase and ferritin. Lab Invest (1995) 1.34
Mechano-chemical control of human endothelium orientation and size. J Cell Biol (1989) 1.33
Potentiation of complement (C5a)-induced granulocyte aggregation by cytochalasin B. J Lab Clin Med (1978) 1.33
Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage. Semin Hematol (1979) 1.33
Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost (2006) 1.33
Effect of intravascular complement activation on granulocyte adhesiveness and distribution. Blood (1978) 1.31
Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol (1995) 1.31
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem (2000) 1.29
Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol (1997) 1.29
Recessive super-suppression in yeast. Mol Gen Genet (1974) 1.29
A possible role for cyclic nucleotides in the regulation of erythrocyte shape and permeability. J Lab Clin Med (1976) 1.28
Studies of energy transport in heart cells. Mitochondrial isoenzyme of creatine phosphokinase: kinetic properties and regulatory action of Mg2+ ions. Eur J Biochem (1975) 1.28
Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. Blood (1988) 1.27
Membrane abnormalities of irreversibly sickled cells. Semin Hematol (1979) 1.27
C-terminal truncation of the Sup35 protein increases the frequency of de novo generation of a prion-based [PSI+] determinant in Saccharomyces cerevisiae. Curr Genet (1998) 1.26
Altered sulfhydryl reactivity of hemoglobins and red blood cell membranes in congenital Heinz body hemolytic anemia. J Clin Invest (1968) 1.26
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res (2011) 1.25
Recessive nonsense-suppression in yeast: further characterization of a defect in translation. FEBS Lett (1976) 1.24
Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med (1990) 1.23
The role of hemoglobin heme loss in Heinz body formation: studies with a partially heme-deficient hemoglobin and with genetically unstable hemoglobins. J Clin Invest (1970) 1.22
Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol (1995) 1.22
Stretch affects phenotype and proliferation of vascular smooth muscle cells. Mol Cell Biochem (1995) 1.21
Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg (1981) 1.21